Tag Archives: P-selectin

Pancreatic cancer drug that mimics heparin halted in Phase 2 for lack of efficacy

A Phase 2 study of necuparanib (from Momenta Pharmaceuticals) was halted following an interim futility analysis. The data and safety monitoring board (DSMB) ran the analysis once 57 patients in the 120-person trial had died, leading to the conclusion that necuparanib was showing insufficient efficacy to justify continuing the study. Continue reading